SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-133791
Filing Date
2024-05-08
Accepted
2024-05-08 07:52:01
Documents
15
Period of Report
2024-05-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d811605d8k.htm   iXBRL 8-K 58596
2 EX-99.1 d811605dex991.htm EX-99.1 20913
6 GRAPHIC g811605g0507211230076.jpg GRAPHIC 3606
  Complete submission text file 0001193125-24-133791.txt   223666

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20240508.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20240508_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20240508_pre.xml EX-101.PRE 11258
18 EXTRACTED XBRL INSTANCE DOCUMENT d811605d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 24924285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)